Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reissue Patent
2011-03-01
2011-03-01
Landsman, Robert (Department: 1646)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S325000, C435S069100, C435S320100, C530S350000, C536S023500
Reissue Patent
active
RE042190
ABSTRACT:
The invention disclosed in this patent document relates to transmembrane receptors, more particularly to endogenous, human orphan G protein-coupled receptors.
REFERENCES:
patent: 3197368 (1965-07-01), Lappe et al.
patent: 5462856 (1995-10-01), Lerner et al.
patent: 5514578 (1996-05-01), Hogness et al.
patent: 5532157 (1996-07-01), Fink
patent: 5573944 (1996-11-01), Kirschner et al.
patent: 5639616 (1997-06-01), Liao et al.
patent: 5750353 (1998-05-01), Kopin et al.
patent: 5891646 (1999-04-01), Barak et al.
patent: 5932445 (1999-08-01), Lal et al.
patent: 5942405 (1999-08-01), Ames et al.
patent: 6051386 (2000-04-01), Lerner et al.
patent: 6221660 (2001-04-01), Bonini et al.
patent: 6468756 (2002-10-01), Bonini et al.
patent: 6555339 (2003-04-01), Liaw et al.
patent: 6555344 (2003-04-01), Matsumoto et al.
patent: 6653086 (2003-11-01), Behan et al.
patent: 7083933 (2006-08-01), Griffin et al.
patent: 7108991 (2006-09-01), Chen et al.
patent: 2003/0064381 (2003-04-01), Feder et al.
patent: 2003/0125539 (2003-07-01), Bonini et al.
patent: 2003/0139590 (2003-07-01), Oshishi et al.
patent: 2003/0148450 (2003-08-01), Chen et al.
patent: 2003/0180813 (2003-09-01), Ohishi et al.
patent: 2007/0122878 (2007-05-01), Chen et al.
patent: 2008/0199889 (2008-08-01), Chen et al.
patent: 2135253 (1996-05-01), None
patent: 2362906 (2000-08-01), None
patent: 0 860 502 (1998-08-01), None
patent: 0860502 (1998-08-01), None
patent: 0 899 332 (1999-03-01), None
patent: 0899332 (1999-03-01), None
patent: 0 913 471 (1999-05-01), None
patent: 0913471 (1999-05-01), None
patent: 0 913 471 (1999-05-01), None
patent: 1075493 (2001-02-01), None
patent: 1092727 (2001-04-01), None
patent: 1 092 727 (2001-04-01), None
patent: 1 092 727 (2001-04-01), None
patent: 1338651 (2003-08-01), None
patent: WO 98/00552 (1988-01-01), None
patent: WO 93/25677 (1993-12-01), None
patent: WO 97/11159 (1997-03-01), None
patent: WO 97/20045 (1997-06-01), None
patent: WO 97/21731 (1997-06-01), None
patent: WO 97/24929 (1997-07-01), None
patent: WO 98/31810 (1998-07-01), None
patent: WO 98/34948 (1998-08-01), None
patent: WO 98/38217 (1998-09-01), None
patent: WO 98/39441 (1998-09-01), None
patent: WO 98/46995 (1998-10-01), None
patent: WO 98/50549 (1998-11-01), None
patent: WO 99/24463 (1999-05-01), None
patent: WO 99/24569 (1999-05-01), None
patent: WO 99/25830 (1999-05-01), None
patent: WO 99/42484 (1999-08-01), None
patent: WO 99/46378 (1999-09-01), None
patent: WO 99/52927 (1999-10-01), None
patent: WO 99/52945 (1999-10-01), None
patent: WO 99/52946 (1999-10-01), None
patent: WO 99/55732 (1999-11-01), None
patent: WO 99/55733 (1999-11-01), None
patent: WO 99/55734 (1999-11-01), None
patent: WO 99/64436 (1999-12-01), None
patent: WO 00/11015 (2000-03-01), None
patent: WO 00/11166 (2000-03-01), None
patent: WO 00/11170 (2000-03-01), None
patent: WO 00/22129 (2000-04-01), None
patent: WO 00/22131 (2000-04-01), None
patent: WO 00/23588 (2000-04-01), None
patent: WO 00/26369 (2000-05-01), None
patent: WO 00/28028 (2000-05-01), None
patent: WO 00/31258 (2000-06-01), None
patent: WO 00/31258 (2000-06-01), None
patent: WO 00/42026 (2000-07-01), None
patent: WO 00/50562 (2000-08-01), None
patent: WO 00/12707 (2000-09-01), None
patent: WO 01/32864 (2001-05-01), None
patent: WO 01/36473 (2001-05-01), None
patent: WO 01/42288 (2001-06-01), None
patent: WO 01/87929 (2001-11-01), None
patent: WO 02/16548 (2002-02-01), None
patent: WO 02/44362 (2002-06-01), None
patent: WO 02/44362 (2002-06-01), None
patent: WO 02/64789 (2002-08-01), None
Allenby et al., “Binding of 9-cis-retinoic acid and all-trans-retinoic acid to retinoic acid receptors alpha, beta, and gamma. Retinoic acid receptor gamma binds all-trans-retinoic acid preferentially over 9-cis-retinoic acid,” Journal of Biological Chemistry, 269(24):16689-16695 (1994).
Berdyshev et al., “Effects of cannabinoid receptor ligands on LPS-induced pulmonary inflammation in mice,” Life Sciences, 63:PL125-129 (1998).
Bhagwandin et al., “Structure and activity of human pancreasin, a novel tryptic serine peptidase expressed primarily by the pancreas,” Journal of Biological Chemistry, 278(5):3363-3371 (2003).
Bjarnadottir et al., “Comprehensive repertoire and phylogenetic analysis of the G protein-coupled receptors in human and mouse,” Genomics, 88(3):263-273 (2006).
Bowie et al., “Deciphering the message in protein sequences: tolerance to amino acid substitutions,” Science, 247(4948): 1306-1310 (1990).
Bowman et al.,(eds) In: Textbook of Pharmacology 2nd Edition, Blackwell Scientific Publications, Lonon, Chapter 29 (1980).
Byrnes et al., “Recent therapeutic advances in thrombotic thrombocytopenic purpura,” Seminars in Thrombosis and Hemostasis, 5(3):199-215 (1979).
Cadas et al., “Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain,” Journal of Neuroscience, 17(4):1226-1242 (1997).
Calignano et al., “Control of pain initiation by endogenous cannabinoids,” Nature, 394(6690):277-281 (1998).
Chan et al., “Antisense oligonucleotides: from design to therapeutic application,” Clinical and Experimental Pharmacology and Physiology, 33(5-6):533-540 (2006).
Di Marzo et al., “Interactions between synthetic vanilloids and the endogenous cannabinoid system,” FEBS Letters 436(6):449-454 (1998).
Di Tomaso et al., “Brain cannabinoids in chocolate,” Nature, 382(6593):677-678 (1996).
Elshourbagy et al., “Receptor for the pain modulatory neuropeptides FF and AF is an orphan G protein-coupled receptor,” Journal of Biological Chemistry, 275(34), 25965-25971 (2000).
Fernandez et al., “Structure, function, and inhibition of chemokines,” Annual Review of Pharmacology and Toxicology, 42:469-499 (2002).
Fujimoto et al., “Phasic effects of glucose, phospholipase A2, and lysophospholipids on insulin secretion,” Endocrinology, 120(5):1750-1757 (1987).
Fujimoto et al., “Phasic effects of glucose, p-hydroxymercuribenzoate, and lysophosphatidylcholine on insulin secretion from HIT cells,” Diabetes, 38(5):625-628 (1989).
Gudas et al., “Cellular Biology and Biochemistry of the Retinoids,” In: The retinoids: Biology, Chemistry and Medicine (Sporn MB; Roberts, AB, Goodman DS eds) 2nd edition, Raven Press, New York, pp. 443-520 (1994).
Hammonds et al., “Regulation and specificity of glucose-stimulated insulin gene expression in human islets of Langerhans,” FEBS Letters, 223(1): 131-137 (1987).
Hilier et al., “Generation and analysis of 280,000 human expressed sequence tags,” Genome Research, 6(9):807-828 (1996).
Hofmann et al., “Retinoids In Development,” In: The retinoids: Biology, chemistry and medicine (Sporn, MB, Roberts, AB, Goodman DS eds) 2nd edition, Raven Press, New York, pp. 387-441 (1994).
Huang et al., “Discovery of human antibodies against the C5aR target using phage display technology,” Journal of Molecular Recognition, 18(4):327-333 (2005).
Inagaki et al., “c-Jun represses the human insulin promoter activity that depends on multiple cAMP response elements,” PNAS, 89(3):1045-1049 (1992).
Inagaki et al., “Regulation of Human Insulin Gene Expression by a cAMP,” Molecular Genetics of Diabetes, 52(10):2528-2532 (1994).
Jaggar et al., “The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain,” Pain, 76(1-2)189-199 (1998).
Jaggar et al., “The endogenous cannabinoid anandamide, but not the CB2 ligand palmitoylethanolamide, prevents the viscero-visceral hyper-reflexia associated with inflammation of the rat urinary bladder,” Neuroscience Letters, 253(2):123-126 (1998).
Lowe et al., “Cloning and characterization of human pancreatic lipase cDNA,” Journal of Biological Chemistry, 264(33): 20042-20048 (1989).
Lowe et a
Chen Ruoping
Leonard James N.
Arena Pharmaceuticals Inc.
Chandra Gyan
Doss Raymond M.
Landsman Robert
Mangasarian Karen
LandOfFree
Method of identifying a compound for inhibiting or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of identifying a compound for inhibiting or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of identifying a compound for inhibiting or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2738106